New Data Show Amgen's Repatha ® (evolocumab) Significantly Reduced LDL-C And Non-HDL-C In High-risk Patients With Type 2 Diabetes

Data Presented at the 78th Scientific Sessions of the American Diabetes Association THOUSAND OAKS, Calif., June 23, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data that show Repatha® (evolocumab) significantly reduced low-density lipoprotein cholesterol (LDL-C) and non-high density lipoprotein cholesterol (non-HDL-C) in patients with Type 2 diabetes and hypercholesterolemia or mixed dyslipidemia, taking the maximum tolerated dose of moderate/high-intensity statin therapy. BANTING was a dedicated study evaluating the efficacy of Repatha (monthly dosing), in lowering LDL-C and improving other lipid levels in patients with Type 2 diabetes.1 In addition to meeting criteria...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news